Product image of Icatibant Stada (Icatibant) supplied by GNH India

Icatibant Stada

Active Ingredient:
Icatibant
Origin:
EU

Icatibant Stada (Icatibant)

Icatibant, the active ingredient in Icatibant Stada, is a Bradykinin B2 receptor antagonist presented as a sterile solution for injection for subcutaneous use. It is indicated for the treatment of acute hereditary angioedema (HAE) attacks in patients with confirmed HAE types I and II.

GNH India supplies Icatibant Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing products sourced from the European Union market to meet global therapeutic needs.

Manufacturer / TM Owner

Stada Arzneimittel Ag

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Icatibant acts on the bradykinin pathway to relieve swelling in hereditary angioedema.
  • Hereditary angioedema type I: rapid reduction of swelling during acute attacks.
  • Hereditary angioedema type II: rapid reduction of swelling during acute attacks.
  • Acute hereditary angioedema in adults: shortens duration and severity of symptoms.

How It Works

  • Icatibant is a competitive antagonist of the bradykinin B2 receptor. By binding to this receptor, it blocks the actions of bradykinin, preventing the vasodilation and increased vascular permeability that lead to the swelling characteristic of hereditary angioedema. The inhibition of the receptor therefore curtails the cascade that produces angioedema episodes.

Side Effects

Common Side Effects

  • Injection site pain: discomfort at the subcutaneous injection site.
  • Redness or erythema: localized skin reddening.
  • Swelling at injection site: mild local edema.
  • Nausea: occasional gastrointestinal upset.
  • Headache: mild to moderate head pain.
  • Dizziness: transient light‑headedness.

Serious or Rare Side Effects

  • Hypersensitivity reactions: rash, itching, or hives.
  • Anaphylaxis: severe, potentially life‑threatening allergic response.
  • Severe hypotension: marked drop in blood pressure.
  • Angioedema unrelated to HAE: unexpected swelling.
  • Urticaria: hives appearing after administration.
  • Thrombocytopenia: low platelet count observed in rare cases.

Precautions & Warnings

Before initiating therapy, consider the following precautions:

  • Confirm diagnosis: ensure the patient has hereditary angioedema before use.
  • Monitor for hypersensitivity: watch for signs of allergic reaction after injection.
  • Cardiovascular caution: use carefully in patients with known heart disease or unstable blood pressure.
  • Avoid in known allergy: do not administer to individuals with hypersensitivity to icatibant or any excipients.
  • Pregnancy and lactation: safety not established; weigh risks and benefits before prescribing.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Icatibant may interact with other medications that influence bradykinin or blood pressure.

Major Interactions (Avoid)

  • ACE inhibitors: increase bradykinin levels, raising risk of angioedema.
  • Other bradykinin B2 antagonists: additive antagonism may lead to excessive blockade.
  • Renin‑angiotensin system blockers: potential for enhanced hypotensive effects.

Moderate Interactions (Monitor Closely)

  • Antihistamines: may mask early signs of hypersensitivity.
  • Corticosteroids: could alter immune response, requiring observation.
  • Concurrent injectable biologics: may increase incidence of injection‑site reactions.

Frequently Asked Questions

Icatibant Stada is used to treat acute attacks of hereditary angioedema (HAE) in patients with confirmed type I or type II disease. It works by rapidly reducing swelling and discomfort associated with these episodes.

Icatibant blocks the bradykinin B2 receptor, preventing bradykinin from causing vasodilation and increased vascular permeability. This inhibition stops the cascade that leads to the swelling seen in hereditary angioedema.

The dose of icatibant is determined by the prescribing clinician based on the patient’s condition, weight, and clinical response. The medication is administered as a subcutaneous injection according to the prescriber’s instructions.

Safety data for icatibant in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Icatibant is a selective bradykinin B2 receptor antagonist, whereas other options such as C1‑esterase inhibitor concentrates replace a deficient protein. Icatibant provides a rapid, targeted approach to block bradykinin‑mediated swelling, offering an alternative for patients who prefer a subcutaneous self‑administered therapy.

Icatibant Stada should be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and do not freeze or shake the solution before use.

Icatibant is given as a single subcutaneous injection into the abdomen or thigh. The injection is performed by a trained healthcare professional or by the patient after proper instruction, using the supplied pre‑filled syringe.

Serious risks include hypersensitivity reactions such as anaphylaxis, severe hypotension, and rare cases of angioedema unrelated to HAE. Patients should be monitored closely after the first dose for any signs of these reactions.

Icatibant should not be used in individuals with known hypersensitivity to icatibant or any component of the formulation. Caution is also advised for patients with unstable cardiovascular conditions until safety is confirmed by a physician.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Icatibant

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT